| Outcome Measures: |
Primary: Safety outcomes_Adverse events occurred during clinical trials, Safety outcomes_Adverse events occurred during clinical trials, from baseline up to 52 weeks|Safety outcomes_ Change of blood pressure, Safety outcomes_ Change of blood pressure, from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP|Safety outcomes_ Change of heartbeat, Safety outcomes_ Change of heartbeat, from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP|Safety outcomes_ Change of body temperature, Safety outcomes_ Change of body temperature, from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP|Efficacy outcome_Change of HbA1c, Efficacy outcome_Change of HbA1c, from Baseline at Week 8, 16, 24, 38, and 52 after administration of the IP|Efficacy outcome_Change of FPG, Efficacy outcome_Change of FPG, from baseline at Week 8, 16, 24, 38, and 52 after administration of the IP|Efficacy outcome_Proportion of subjects achieving HbA1c target of < 6.5%, Efficacy outcome_Proportion of subjects achieving HbA1c target of \< 6.5%, at Weeks 8, 16, 24, 38 and 52 after administration of the IP|Efficacy outcome_Proportion of subjects achieving HbA1c target of < 7.0 %, Efficacy outcome_Proportion of subjects achieving HbA1c target of \< 6.5%, at Weeks 8, 16, 24, 38 and 52 after administration of the IP |
|
